These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33724140)

  • 1. Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
    Galan L; Gonzalez-Moreno J; Martínez-Sesmero JM; Muñoz-Beamud F; Santos-Rubio MD; Tran D; Lebeau P; Stewart M; Mallaina P; Tarilonte P; Peral C; Rozenbaum MH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):967-973. PubMed ID: 33724140
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
    Gertz MA; Mauermann ML; Grogan M; Coelho T
    Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
    Samjoo IA; Salvo EM; Tran D; Amass L; Stewart M; Cameron C
    Curr Med Res Opin; 2020 May; 36(5):799-808. PubMed ID: 32011182
    [No Abstract]   [Full Text] [Related]  

  • 4. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
    Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In brief: Tafamidis (Vyndaqel; Vyndamax) for transthyretin amyloid cardiomyopathy.
    Med Lett Drugs Ther; 2020 Jan; 62(1590):16. PubMed ID: 31999671
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
    Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
    Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
    Zibert A; Hüsing-Kabar A; Schmidt H
    Dtsch Med Wochenschr; 2019 Oct; 144(20):1438-1443. PubMed ID: 31594020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
    Buxbaum JN
    Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy.
    Inês M; Coelho T; Conceição I; Landeiro F; de Carvalho M; Costa J
    Amyloid; 2020 Jun; 27(2):89-96. PubMed ID: 31854198
    [No Abstract]   [Full Text] [Related]  

  • 13. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Huber P; Flynn A; Sultan MB; Li H; Rill D; Ebede B; Gundapaneni B; Schwartz JH
    Amyloid; 2019 Dec; 26(4):203-209. PubMed ID: 31353964
    [No Abstract]   [Full Text] [Related]  

  • 15. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 16. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis.
    Mahfouz M; Maruyama R; Yokota T
    Methods Mol Biol; 2020; 2176():87-98. PubMed ID: 32865784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
    Lin H; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Aug; 20(12):1529-1530. PubMed ID: 31124741
    [No Abstract]   [Full Text] [Related]  

  • 18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
    Salvo EM; Samjoo IA; Tran D; Cameron C
    Expert Opin Pharmacother; 2019 Aug; 20(12):1527-1528. PubMed ID: 31124724
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of cardiac transthyretin amyloidosis: an update.
    Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
    Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.